Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

April 24 (Reuters) - Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood ...

BridgeBio ( BBIO) rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's ( ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Anchored by TV spots and sports media placements, the Every Inch Matters campaign positions the projected number one overall ...

Pfizer’s dividend yield has surged to 6.3% after a 55% share price drop since 2021, prompting concerns about its sustainability. Management has pledged to maintain the payout, but payout ratios above ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...